StageZero Life Sciences Ltd.
SZLS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -32.97% | -50.83% | -32.96% | -6.74% | -6.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.97% | -50.83% | -32.96% | -6.74% | -6.74% |
| Cost of Revenue | -11.29% | -45.82% | -48.40% | -12.71% | 3.83% |
| Gross Profit | -284.77% | -91.11% | -14.00% | 21.76% | -57.27% |
| SG&A Expenses | -69.64% | -14.80% | -61.38% | -36.37% | -44.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.45% | -32.76% | -59.80% | -31.21% | -31.21% |
| Operating Income | 53.71% | 15.29% | 76.45% | 45.28% | 45.28% |
| Income Before Tax | 51.42% | -61.77% | 78.68% | -1,722.39% | -1,722.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.42% | -61.77% | 78.68% | -1,722.39% | -1,722.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.42% | -61.77% | 78.68% | -1,722.39% | -1,722.39% |
| EBIT | 53.71% | 15.29% | 76.45% | 45.28% | 45.28% |
| EBITDA | 53.36% | 14.41% | 76.81% | 40.81% | 40.81% |
| EPS Basic | 60.49% | -47.22% | 84.50% | -1,340.00% | -1,520.00% |
| Normalized Basic EPS | 60.78% | -50.00% | 83.87% | -104.55% | -131.82% |
| EPS Diluted | 60.49% | -47.22% | 84.50% | -1,340.00% | -1,520.00% |
| Normalized Diluted EPS | 60.78% | -50.00% | 83.87% | -104.55% | -131.82% |
| Average Basic Shares Outstanding | 22.10% | 11.62% | 36.38% | 18.39% | 5.54% |
| Average Diluted Shares Outstanding | 22.10% | 11.62% | 36.38% | 18.39% | 5.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
